Press Release

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 22, 2024-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from three studies will demonstrate the power of the Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help to further personalize treatment of the disease. The findings will be presented at ENDO 2024, the annual meeting of The Endocrine Society, which will take place June 1-4 in Boston.

“Molecular testing in thyroid cancer currently focuses primarily on whether a patient’s thyroid nodule is benign or cancerous, and whether specific gene mutations are present,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology. “The data to be presented at ENDO 2024 looks beyond individual gene mutations and explores the potential of novel molecular signatures and alterations to provide more-granular, prognostic information. This may ultimately help clinicians guide more individualized care based on the molecular characteristics of each patient’s tumor. These findings are from studies using Afirma GRID, a research-use-only tool that leverages Veracyte's whole-transcriptome approach, which enables the scientific community to advance understanding of thyroid cancer biology.”

Following are details for the Afirma GRID-focused research studies that will be presented at ENDO 2024 in the Boston Convention & Exhibition Center:

Additional information about these presentations and Veracyte’s participation at ENDO 2024 can be found at the company’s booth (#709).

About Afirma GRID

The Afirma GRID database is inclusive of the sequencing of over 21,000 expressed genes for nearly 200,000 patients with thyroid nodules (benign and malignant) and is used by Veracyte and its partners to contribute to continued research that helps advance understanding of thyroid tumors. Afirma GRID information is available on a Research-Use-Only basis. More information about Afirma GRID can be found here.

About the Afirma GSC

Veracyte’s flagship Afirma Genomic Sequencing Classifier (GSC) was developed with RNA whole-transcriptome-derived sequencing and machine learning technology and helps physicians identify patients with benign thyroid nodules among those whose fine needle aspiration (FNA) biopsy results are indeterminate by cytopathology so that they can potentially avoid unnecessary thyroid surgery. The Afirma GSC also includes Xpression Atlas, the largest thyroid gene and fusion variant panel available, to help inform treatment decisions for patients whose genomic test or cytopathology results are suspicious for cancer. Veracyte also enables physicians to order DNA testing of the TERT promoter gene, which is performed on the same FNA sample, to help further guide treatment decision-making. More information about the Afirma GSC can be found here.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to the potential for the Afirma GRID research-use-only tool to support scientific community advancement in understanding of thyroid cancer biology. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact Afirma GRID can have on scientific advancements in thyroid cancer and, in turn, patients. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024, and our 10-Q filed on May 8, 2024. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522130721/en/

Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
media@veracyte.com
650-380-4413

Source: Veracyte, Inc.